Adlai Nortye Ltd. (NASDAQ:ANL - Get Free Report)'s stock price traded up 2.4% on Friday . The company traded as high as $2.10 and last traded at $1.85. Approximately 2,484 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 13,363 shares. The stock had previously closed at $1.81.
Adlai Nortye Stock Performance
The business's 50-day simple moving average is $1.95 and its 200 day simple moving average is $2.16.
About Adlai Nortye
(
Get Free Report)
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Further Reading
Before you consider Adlai Nortye, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.
While Adlai Nortye currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
